



The Open Public Health Journal

Content list available at: <https://openpublichealthjournal.com>

Supplementary Material



Effect of Solution-focused Counseling on Depression and Quality of Life in Women under Mastectomy: A Randomized Clinical Trial

Leila Pirzadi¹, Katayon Vakilian^{1,*}, Fereshteh Farzan Azar¹ and Effat Norouzi²

¹Medical School, Arak University of Medical Sciences, Arak, Iran

²Department of Psychology, Islamic Azad University of Majlesi, Majlesi, Iran

CONSORT 2010 checklist of information to include when reporting a randomised trial*.

Section/Topic	Item No	Checklist Item	Reported on Page No
Title and abstract			
	1a	Identification as a randomised trial in the title	Page 1 in title
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	Page 1 , in abstract
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	Yes, in page 2 and 3
	2b	Specific objectives or hypotheses	Page in page 3 last paragraph
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	3a, Yes, page 4 in Trial design and participants section , in first line 3b, not applicable
Participants	4a	Eligibility criteria for participants	Yes in Trial design and participants section ,page 4 in second paragraph section
	4b	Settings and locations where the data were collected	Settings and locations included in methods in Setting of the study in page 3 5- In page 4, line 11-14
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	6a-Yes in In instrument and outcome in page 6
	6b	Any changes to trial outcomes after the trial commenced, with reasons	6 b. N/A
Sample size	7a	How sample size was determined	It explained in sample size section page 5
	7b	When applicable, explanation of any interim analyses and stopping guidelines	N/A
Randomisation:			

contd.....

Section/Topic	Item No	Checklist Item	Reported on Page No
Sequence generation	8a	Method used to generate the random allocation sequence	8a- Implementation section In Methods in Trial design and participants section ,paragraph 2 ,line 22,page 4
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	8 b-Implementation section In Methods in Trial design and participants section ,paragraph 2 ,line 20,page 4
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Implementation section In Methods in Trial design and participants section ,paragraph 2 ,line 22,page 4
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	10- = line 5, page 5
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	Not applicable
	11b	If relevant, description of the similarity of interventions	Not applicable
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	Statistical Tests were page 6
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	N/A
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	Trial design and participants in page 4 and in first paragraph in Statistical tests
	13b	For each group, losses and exclusions after randomisation, together with reasons	<i>Yes in Methods in Trial design and participants in page 4</i> . also in section result in Samples' characteristics
Recruitment	14a	Dates defining the periods of recruitment and follow-up	Trial design and participants in page 4 ,line 15
	14b	Why the trial ended or was stopped	n/A
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 2
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	Table 3
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Table 3
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Table3
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	N/A
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	N/A
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	Limitations brought out in Conclusion section
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	N/A
Other information			
Registration	23	Registration number and name of trial registry	After keywords of abstract
Protocol	24	Where the full trial protocol can be accessed, if available	<i>IRCT</i>
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	Funding section line 2

Note: *We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.